1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
  5. > Global Market Study on Osteoporosis Drugs: Asia Pacific to Witness Highest Growth by 2022

Osteoporosis is a progressive, skeletal disease, leading to fragile and abnormally porous bones. It is characterized by decrease in bone density, strength, and micro-architectural deterioration of bone tissue resulting in thinning or weakening of bones with an increased propensity of fractures. Primary and secondary osteoporosis are the major types of osteoporosis. Some of the factors leading to osteoporosis are genetic factor, aging, lack of calcium and vitamin D, smoking, lack of exercise, low body weight, excessive alcohol consumption, history of rheumatoid arthritis, menopause, and certain medication. Osteoporosis can be diagnosed using X-ray and can be confirmed by bone density scan. Dual energy X-ray absorptiometry (DEXA) is the common bone density test used to measure the density of bones. Treatment for osteoporosis begins with a change in lifestyle and diet. It can be prevented and treated with the help of calcium and vitamin D supplements, exercise, and osteoporosis medications. Prevalence of osteoporosis is high among people aged 60 years and above. Moreover, estrogen plays a vital role in regulating the bone growth process in women. Post menopause, bone breakdown outpaces the building of new bone matter. The rate of bone loss in women increases after menopause, leading to the threat of developing osteoporosis.

North America is the largest market for osteoporosis drugs due to increasing geriatric population, growing investment in R&D for the discovery of innovative drugs, and rising prevalence of lifestyle-associated diseases in the region. Asia-Pacific is expected to exhibit high growth rates over the following five years in the global osteoporosis drugs market. China and India are expected to be the fastest-growing markets for osteoporosis drugs in Asia Pacific. Some of the key driving forces for the osteoporosis drugs market in emerging countries are rising geriatric population, a large pool of patients, changing lifestyles, increasing healthcare expenditure, and growing awareness about osteoporosis care in these regions.

Rising geriatric population, changing lifestyle impinging bone health, and increasing prevalence of osteoporosis in post-menopausal women are some of the factors driving the growth of the global osteoporosis drugs market. In addition, increasing awareness about osteoporosis care and growing investments in R&D for the discovery of innovative drugs are also fueling the growth of the market. On the other hand, side effects and complications such as irritable bowel syndrome, nausea, and ulcers in stomach or esophagus, associated with osteoporosis drugs and patent expiration of osteoporosis drugs are inhibiting growth of the global osteoporosis drugs market.

This report provides in-depth analysis and estimation of the osteoporosis drugs market for 2015– 2022, considering 2014 as the base year for calculation. Moreover, data pertaining to current market dynamics, including market drivers, restraints, trends, and recent developments, has been provided in the report.

Key segments covered in this report are:

By drugs type

Bisphosphonates
Parathyroid Hormone Therapy Drugs
Calcitonin
Selective Estrogen Receptors Modulators (SERMs)
RANK Ligand Inhibitors

Key geographies evaluated in this report are:

North America

U.S.

Europe

France, Germany, and the UK
Rest of Europe

APAC

China
India
Japan
Rest of Asia Pacific

Top companies profiled in this report are:

Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Merck & Co, Inc.
Novartis AG
Amgen, Inc.
Novo Nordisk A/S
Actavis plc
Pfizer, Inc.
GlaxoSmithKline plc
Teva Pharmaceutical Industries Ltd

Key features of this report

Drivers, restraints, and challenges shaping the osteoporosis drugs market dynamics
Latest innovations and key events in the market
Analysis of business strategies of the top players in the market
Osteoporosis drugs market estimates and forecasts

Table Of Contents

Global Market Study on Osteoporosis Drugs: Asia Pacific to Witness Highest Growth by 2022
Chapter 1 Preface 8

1.1 Report Description 8

1.2 Research Methodology 9

1.3 Assumptions 9

Chapter 2 Market Synopsis 10

Chapter 3 Porter's Five Forces Analysis 11

3.1 Bargaining Power of Suppliers 11

3.2 Bargaining Power of Buyers 12

3.3 Threat of New Entrants 12

3.4 Threat of Substitutes 12

3.5 Intensity of Rivalry 13

Chapter 4 Industry Overview 14

4.1 Market Definition 14

4.2 Market Drivers 16

4.2.1 Rising geriatric population 16

4.2.2 Change in lifestyle impinging bone health 17

4.2.3 Increasing prevalence of osteoporosis in post-menopausal women 18

4.2.4 Increasing awareness about osteoporosis care 19

4.2.5 Increasing RandD investments in drug discovery and development 20

4.3 Impact Analysis of Market Drivers 20

4.4 Market Restraints 21

4.4.1 Side effects and complications associated with administration of osteoporosis drugs 21

4.4.2 Patent expiration of osteoporosis drugs 22

4.5 Impact Analysis of Market Restraints 23

Chapter 5 Global Market Size and Forecast 24

Chapter 6 Market Size and Forecast by Drug Type 28

6.1 Bisphosphonates 28

6.2 Parathyroid Hormone Therapy Drugs 30

6.3 Calcitonin 32

6.4 Selective Estrogen Receptor Modulators (SERMs) 34

6.5 RANK Ligand Inhibitors (Denosumab) 36

Chapter 7 Market Size and Forecast by Geography 39

7.1 North America 39

7.2 Europe 41

7.3 Asia Pacific 44

Chapter 8 Competitive Scenario 48

8.1 Competitive Analysis 48

Chapter 9 Company Profiles 50

9.1 Eli Lilly and Company 50

9.1.1 Company overview 50

9.1.2 Products and services 50

9.1.3 Financial performance 51

9.1.4 Key developments 51

9.2 F. Hoffmann-La Roche Ltd 52

9.2.1 Company overview 52

9.2.2 Products and services 52

9.2.3 Financial performance 53

9.2.4 Key developments 53

9.3 Merck and Co. Inc. 54

9.3.1 Company overview 54

9.3.2 Products and services 54

9.3.3 Financial performance 55

9.3.4 Key developments 55

9.4 Novartis AG 56

9.4.1 Company overview 56

9.4.2 Products and services 56

9.4.3 Financial performance 57

9.4.4 Key developments 57

9.5 Amgen, Inc. 58

9.5.1 Company Overview 58

9.5.2 Product and Services 58

9.5.3 Financial Performance 58

9.5.4 Recent Developments 59

9.6 Novo Nordisk A/S 60

9.6.1 Company overview 60

9.6.2 Products and services 60

9.6.3 Financial performance 61

9.6.4 Key developments 61

9.7 Actavis plc 62

9.7.1 Company overview 62

9.7.2 Products and services 62

9.7.3 Financial performance 62

9.7.4 Key developments 63

9.8 Pfizer, Inc 65

9.8.1 Company overview 65

9.8.2 Products and services 65

9.8.3 Financial performance 66

9.8.4 Key developments 66

9.9 GlaxoSmithKline plc 67

9.9.1 Company overview 67

9.9.2 Products and services 67

9.9.3 Financial performance 68

9.9.4 Key developments 68

9.10 Teva Pharmaceutical Industries Ltd. 69

9.10.1 Company overview 69

9.10.2 Products and services 69

9.10.3 Financial performance 70

9.10.4 Key developments 70

List of Table

TABLE 1 Market snapshot: osteoporosis drugs market, 2015and 2022 10

TABLE 2 Drivers for osteoporosis drugs market: Impact analysis 20

TABLE 3 Patent expiration of various osteoporosis drugs 22

TABLE 4 Restraints for global osteoporosis drugs market: Impact analysis 23

TABLE 5 Global osteoporosis drugs market size, by region, 2012 - 2014 (US$ Mn) 24

TABLE 6 Global osteoporosis drugs market size, by region, 2015 - 2022 (US$ Mn) 25

TABLE 7 Global osteoporosis drugs market size, by type, 2012 - 2014 (US$ Mn) 26

TABLE 8 Global osteoporosis drugs market size, by type, 2015 - 2022 (US$ Mn) 27

TABLE 9 Risk reduction of fracture with bisphosphonates over 3-4 years 28

TABLE 10 Global bisphosphonates drugs market size, by region, 2012 - 2014 (US$ Mn) 29

TABLE 11 Global bisphosphonates drugs market size, by region, 2015 - 2022 (US$ Mn) 30

TABLE 12 Global parathyroid hormone therapy drugs market size, by region, 2012 - 2014 (US$ Mn) 31

TABLE 13 Global parathyroid hormone therapy drugs market size, by region, 2015 - 2022 (US$ Mn) 32

TABLE 14 Global calcitonin drugs market size, by region, 2012 - 2014 (US$ Mn) 33

TABLE 15 Global calcitonin drugs market size, by region, 2015 - 2022 (US$ Mn) 34

TABLE 16 Global SERMs drugs market size, by region, 2012 - 2014 (US$ Mn) 35

TABLE 17 Global SERMs drugs market size, by region, 2015 - 2022 (US$ Mn) 36

TABLE 18 Global RANK ligand inhibitors drugs market size, by region, 2012 - 2014 (US$ Mn) 37

TABLE 19 Global RANK ligand inhibitors drugs market size, by region, 2015 - 2022 (US$ Mn) 38

TABLE 20 North America osteoporosis drugs market size, by country, 2012 - 2014 (US$ Mn) 40

TABLE 21 North America osteoporosis drugs market size, by country, 2015 - 2022 (US$ Mn) 41

TABLE 22 Europe osteoporosis drugs market size, by country, 2012 - 2014 (US$ Mn) 43

TABLE 23 Europe osteoporosis drugs market size, by country, 2015 - 2022 (US$ Mn) 44

TABLE 24 Asia Pacific osteoporosis drugs market size, by country, 2012 - 2014 (US$ Mn) 46

TABLE 25 Asia Pacific osteoporosis drugs market size, by country, 2015 - 2022 (US$ Mn) 47

TABLE 26 Major products of Eli Lilly and Company 50

TABLE 27 Major products of F. Hoffmann-La Roche, Ltd. 52

TABLE 28 Major products of Merck and Co., Inc. 54

TABLE 29 Major products of Novartis AG 56

TABLE 30 Major products of Amgen, Inc. 58

TABLE 31 Major products of Novo Nordisk A/S 60

TABLE 32 Major products of Actavis plc 62

TABLE 33 Major products of Pfizer, Inc. 65

TABLE 34 Major products of GlaxoSmithKline plc 67

TABLE 35 Major products of Teva Pharmaceutical Industries Ltd. 69

List of Figure

FIG. 1 Osteoporosis drugs market: Porter's five force analysis 11

FIG. 2 Risk factors for osteoporosis 14

FIG. 3 Prevention of osteoporosis 15

FIG. 4 Aging population in major regions, 2000 - 2050 (% share in total population) 17

FIG. 5 Decrease of bone mass with onset of menopause 19

FIG. 6 Global osteoporosis drugs market share, by region, by value, 2014 24

FIG. 7 Global osteoporosis drugs market share, by type, by value, 2014 26

FIG. 8 Global bisphosphonates drugs market share, by region, by value, 2014 29

FIG. 9 Global parathyroid hormone therapy drugs market share, by region, by value, 2014 31

FIG. 10 Global calcitonin drugs market share, by region, by value, 2014 33

FIG. 11 Global SERMs drugs market share, by region, by value, 2014 35

FIG. 12 Global RANK ligand inhibitors drug market share, by region, by value, 2014 37

FIG. 13 North Americaosteoporosis drugs market share, by country, by value, 2014 40

FIG. 14 Number of hip fracture cases in European Union member states, 2000 - 2050 42

FIG. 15 Number of vertebra fracture cases in European Union member states, 2000 - 2050 42

FIG. 16 Europe osteoporosis drugs market share, by country, by value, 2014 43

FIG. 17 Asia Pacific osteoporosis drugs market share, by country, by value, 2014 46

FIG. 18 Drug focus analysis of osteoporosis drugs market 48

FIG. 19 Revenue and net income of Eli Lilly and Company, 2012-2014 (US$ Mn) 51

FIG. 20 Sales and net income of F. Hoffmann-La Roche, Ltd., 2012-2014 (US$Mn) 53

FIG. 21 Sales and net income of Merck and Co., Inc., 2012-2014 (US$Mn) 55

FIG. 22 Net sales and net income of Novartis AG, 2012-2014 (US$Mn) 57

FIG. 23 Total revenue and net income of Amgen, Inc., 2012-2014 (US$Mn) 59

FIG. 24 Novo Nordisk's net sales and net profit, 2012 - 2014 (US$ Mn) 61

FIG. 25 Net revenue and net income of Actavis plc, 2012-2014 (US$ Mn) 63

FIG. 26 Revenue and net income of Pfizer, Inc., 2012-2014 (US$Mn) 66

FIG. 27 Turnover and total profit attributable to stakeholders of GlaxoSmithKline plc, 2012-2014 (US$Mn) 68

FIG. 28 Net revenue and net income of Teva Pharmaceutical Industries Ltd., 2012-2014 (US$Mn) 70

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Systemic Lupus Erythematosus Market: By Therapies (Antimalarial Drugs, Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids Cytotoxic & Immunosuppressive Drugs, Biologics, Small Molecules) & By Region (Asia-Pacific, Others)-Forecast (2016-2021)

Systemic Lupus Erythematosus Market: By Therapies (Antimalarial Drugs, Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids Cytotoxic & Immunosuppressive Drugs, Biologics, Small Molecules) & By Region (Asia-Pacific, Others)-Forecast (2016-2021)

  • $ 5250
  • Industry report
  • September 2016
  • by Industry ARC

Systemic lupus erythematosus, also commonly known as lupus, is an autoimmune disease which results in inflammation of tissues in the body with common symptoms like fever, fatigue, skin rashes, malaise, ...

Epiomic Epidemiology Series: Osteoarthritis Forecast in 9 Major Markets 2016-2026

Epiomic Epidemiology Series: Osteoarthritis Forecast in 9 Major Markets 2016-2026

  • $ 5112
  • Industry report
  • October 2016
  • by Black Swan Analysis Ltd132

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Osteoarthritis in 9 Major Markets Osteoarthritis (OA), also known as degenerative joint disease / degenerative arthritis, is an inflammation ...

Global Osteoporosis Drugs Market Size, Share, Development, Growth and Demand Forecast to 2022- Industry Insights by Drug Class

Global Osteoporosis Drugs Market Size, Share, Development, Growth and Demand Forecast to 2022- Industry Insights by Drug Class

  • $ 5100
  • Industry report
  • November 2016
  • by P&S Market Research

The global osteoporosis drugs market was worth $8,835.4 million in 2015 and it is expected to grow at a CAGR of 3.8% during 2016-2022. Among the various drug classes, the rank ligand inhibitors segment ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.